Meet the ICON Biotech team at #ESMO24, booth #423 to learn how we’re partnering with biotechnology organisations to provide industry-recognised, scientific leadership and consulting to plan and deliver oncology clinical trials, from small molecules to biologics, combination products, devices, ATMPs and companion diagnostics. https://ow.ly/XEhe50T2NfM
Info
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
- Website
-
http://www.iconplc.com
Externer Link zu ICON plc
- Branche
- Biotechnologieforschung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Dublin
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- Medical Device, Therapeutics, Government and Public Health Solutions, Clinical Research Services, Commercialisation and Outcomes, Oncology, Value Based Healthcare, Clinical Trials, Patient Recruitment, Innovation, Regulatory Affairs, Strategic Consulting, Medical Affairs und Global Patient Insights & Engagement
Orte
Beschäftigte von ICON plc
Updates
-
Register for our webinar 17 September at 11:00 EST to explore the techniques and best practices in survival analysis for health economic models. Learn from experts Tim Baker and Manikanta Dasari about recent applications and lessons learned in dealing with immature data. Click here to register today: https://ow.ly/ZkbY50SKHAT #HEOR #HealthEconomics #SurvivalAnalysis #Webinar
-
-
Bioanalysis of immunogenicity is critical for the development of therapeutic proteins, as immunogenicity can affect both the safety and efficacy of biologic drugs. High-quality approaches for tiered detection, characterization, or quasi-quantification of anti-drug antibodies (ADAs) require up-to-date knowledge of analytical methodologies, regulatory guidelines and industry best practices. To ensure high-quality approaches for immunogenicity testing, it is necessary to grasp a wide understanding of the needs and expectations of companies that are developing drugs that may initiate immunogenicity. Flexibility in approaches is needed to serve the different needs of each program. In this Spotlight hosted by Bioanalysis Zone we explore the elements involved in the different approaches for immunogenicity assessment, including preclinical ADA assessments, singlicate ADA analysis, or complex assay strategies to determine ADAs for different compounds/antibody modalities. https://ow.ly/7tMR50SCg05
-
-
Learn how a framework to align actively-collected and passively-monitored COAs can streamline your clinical trials and lead to more patient-centred research: https://ow.ly/qyW250T9r5W #ClinicalResearch #COAs #PrecisionMedicine
-
-
ICON's Tim Clark has co-authored a peer-reviewed article on innovative approaches to dose-finding in early-phase oncology trials. With the advent of molecular targeted therapies, traditional methods like the 3+3 design may no longer be optimal. This paper explores Bayesian model-assisted designs and how they perform in real-world scenarios. Read the article to learn more: https://ow.ly/gYq750T9E4K #ClinicalTrials #OncologyResearch
-
-
We are proud to announce that ICON has been recognised by the Mama Godin initiative in Mexico for our commitment to supporting working parents and caregivers. Mama Godin is a prominent initiative dedicated to promoting healthy, safe, inclusive, and resilient work environments promoting flexible work arrangements, providing childcare support, and fostering career development opportunities for parents and caregivers. Due to ICON’s robust family-friendly policies and practices, including flexible work arrangements and comprehensive support for our employees with children, we have been successfully evaluated within the #RankingMamáGodín, which recognizes organizations that excel in these areas. This acknowledgment reflects our ongoing efforts to foster diversity, reduce biases, and create a supportive and equitable work environment for all, which directly aligns with Mama Godin’s mission, and we are honoured to be recognised for our efforts.
-
-
We tailor our medical device development solutions to your product and trial stages using an integrated delivery model to move effectively from concept to market. Join us at #LSIEurope24 to discuss your MedTech strategy. https://ow.ly/a22O50TaJTj #Medtech #MedTechInnovation #Medicaldevices
-
-
Leverage the industry's most experienced reader network of cardiovascular (CV) physicians and experts who will help you navigate the latest changes in cardiac safety trial requirements. Find out how we can help you: https://ow.ly/K5OX50T8z2X
-
-
We’re starting to see an exciting trend towards precision health — the idea that all patients can benefit from technology innovations to prevent illness, treat disease, and even foster wellness, unique to their needs. Find out more about clinical trial strategies and trends in our blog. https://ow.ly/AjKB50T2KZJ #PrecisionHealth #ClinicalTrials #PatientCentric
-
-
ADCs hold immense potential in targeting haematologic and solid tumors. Learn about the journey of ADCs from concept to reality, the challenges overcome and the innovations driving their resurgence in cancer therapeutics. Explore the latest breakthroughs in our new blog post: https://ow.ly/OXm550SZb3W
-
Verbundene Seiten
Ähnliche Seiten
Finanzierung
Letzte Runde
Fremdkapital nach Börsengang2.000.000.000,00 $